Insulin detemir: a long-acting insulin analog for the treatment of Type 1 and 2 diabetes

By Meneghini Luigi F  

Therapy, Vol. 5, Iss. 4, 2008-07 ,pp. : 513-529

Future Medicine

Access to resources Recommend Favorite

Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products

By Bullano Michael F.   Al-Zakwani Ibrahim S.   Fisher Maxine D.   Menditto Laura   Willey Vincent J.  

Current Medical Research and Opinion, Vol. 21, Iss. 2, 2005-02 ,pp. : 291-298

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes

By Hompesch Marcus   Ocheltree Scott M.   Wondmagegnehu Eshetu T.   Morrow Linda A.   Kollmeier Alexa P.   Campaigne Barbara N.   Jacober Scott J.  

Current Medical Research and Opinion, Vol. 25, Iss. 11, 2009-11 ,pp. : 2679-2687

Informa Healthcare

Access to resources Recommend Favorite

Glucose‐lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 554-559

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK

By McEwan Phil   Poole Chris D.   Tetlow Tony   Holmes Paul   Currie Craig J.  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-02 ,pp. : 21-31

Informa Healthcare

Access to resources Recommend Favorite